IF a triple pharmacological regimen consisting of rapamycin (mTOR inhibitor, encapsulated microparticle chow, ~14 ppm dose equivalent established in ITP protocols), trametinib (MEK1/2 inhibitor, ~1 mg/kg/day oral), and anti-IL-11 monoclonal antibody X203 (~10 mg/kg biweekly intraperitoneal injection) is administered to aged C57BL/6J mice (both sexes, treatment initiation at 20 months of age, representing ~60% of median lifespan — an age at which fibrotic, proteostatic, and inflammatory damage is already substantially accumulated),

THEN median lifespan extension exceeding 50% above cohort controls (females: target ≥50%, males: target ≥45%), accompanied by measurable reversal of established hepatic and cardiac fibrosis (assessed by Sirius Red collagen quantification and hydroxyproline content), reduction of circulating SASP markers (IL-6, MMP-3, GDF-15), restoration of proteostatic capacity (autophagic flux via p62/LC3-II ratio in liver and muscle), and attenuation of ERK/STAT3 co-activation in aged tissues will be observed,

BECAUSE the three agents simultaneously block three mechanistically distinct but interacting damage-amplification axes, each of which has accumulated irreversible functional consequences by late midlife, and each of which provides compensatory re-activation signals to the other two pathways in the absence of combined inhibition:

1. Accumulated mTORC1 hyperactivation in aged tissues suppresses autophagy, leading to irreversible accumulation of damaged organelles, oxidized proteins, and dysfunctional mitochondria in long-lived post-mitotic and slow-cycling cells; rapamycin inhibits mTORC1, thereby reactivating autophagic flux to degrade this already-accumulated proteostatic burden (Research Context: rapamycin + trametinib combination, Nature Aging 2025, 34.9% female / 27.4% male median lifespan extension as base regimen).

2. mTOR inhibition alone triggers a well-characterized compensatory feedback loop in which relief of mTORC1-mediated IRS-1 suppression re-engages PI3K→Akt→Ras→MAPK/ERK signaling, blunting the repair benefit of rapamycin alone and sustaining SASP production from senescent cells; trametinib (MEK inhibitor) blocks this ERK reactivation, removing MAPK-driven transcriptional support for SASP cytokines, MMP secretion, and pro-fibrotic TGF-β signaling in established senescent cell populations (Research Context: rapamycin+trametinib additive combination, no negative interaction confirmed in Nature Aging 2025 study).

3. IL-11, upregulated by both the aging microenvironment and by SASP cytokines, signals through gp130→JAK→STAT3 and independently through ERK/MAPK and PI3K, creating a third compensatory bypass node: IL-11 can maintain ERK activation even under MEK inhibition via gp130-coupled alternative ERK recruitment pathways, and can drive mTORC1 re-engagement via PI3K/Akt [SPECULATIVE — proposed cross-talk inferred from IL-11/gp130 canonical signaling and known PI3K convergence; direct triple-node resc...

SENS category: GlycoSENS